Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (487)	5/16/2012 10:00:58 AM
From: Biomaven	Read Replies (1) \| Respond to of 508

Jim, do you think that there will be side effects of the CTGF mAb on chondrogenesis or osteogenesis, such as an increase in bone fractures upon longer term treatment? Knockout mice have shown such signals based on my earlier review of the literature. I think that only time will tell on a question like this. The effect seems much less in adult mice and the mAb isn't going to abrogate all CTGF action. The issue is obviously less important in fatal diseases such as IPF or pancreatic cancer, but may be more of an issue in liver fibrosis. Worst case is probably patients need to take some drug holidays. Peter

To: Biotech Jim who wrote (487)	5/16/2012 8:00:21 PM
From: ghmm	Read Replies (1) \| Respond to of 508

Speaking of Fibrogen here is a link to the changes in their Phase 2 study (just got the update on my RSS feed). I don't know when they started/will start cohort 2. I never count on the clinicaltrials.gov completion date (they have 12/2013). So assuming they wait for that to finish before pursing a Phase 3 and we're looking at several years behind ITMN. If it wasn't open label and the results continued to be promising maybe they'd have a shot with exceptional Phase 2 but that seems unlikely. EDIT forgot link clinicaltrials.gov